Employer Dropping Your GLP-1 Coverage in 2027? Here Are Your Options

If a benefits notice just told you your Wegovy or Zepbound won't be covered next year, you're not alone — a growing number of large employers are cutting GLP-1 coverage for weight loss heading into 2027. The good news: losing employer coverage doesn't mean losing access. Here's what's actually changing, what usually isn't, and eight practical paths forward.

GLP-1 medication coverage options after employer changes

By Health Insurance Network Team

Quick Answer: What Should You Do?

First, read your 2027 formulary — sometimes "dropped" really means new prior authorization or step therapy, not a full exclusion. These cuts almost always target the weight-loss indication (Wegovy, Zepbound, Saxenda); coverage for type 2 diabetes (Ozempic, Mounjaro prescribed for diabetes) typically continues. If the benefit really is gone, your main options are a medical-necessity exception, a marketplace plan whose formulary covers your drug (Open Enrollment starts November 1), and manufacturer self-pay programs commonly in the roughly $350–$500/month range — often about half the list price.

Why This Is Happening — and How Widespread It Is

The short version: total GLP-1 spending keeps climbing even as per-unit prices fall, because new oral GLP-1 pills are bringing in many first-time users. Employers are responding by trimming the weight-loss benefit. The numbers as of mid-2026:

Roughly 10% of employers that currently cover GLP-1s for weight loss plan to drop them in 2027 (Business Group on Health)
In a Mercer survey, about 6% of employers with 500+ workers dropped coverage in 2026 — and about 5% more are considering it for 2027
About two-thirds of large employers cover GLP-1s for weight loss in 2026, but only about 72% of those say they're likely to maintain it
Even insurer Cigna stopped covering the drugs for weight loss for its own employees as of July 2026

The Critical Distinction: Weight Loss vs. Diabetes

Almost all of these cuts target the weight-loss indication — Wegovy, Zepbound, and Saxenda. Coverage for GLP-1s prescribed for type 2 diabetes — Ozempic and Mounjaro when prescribed for diabetes — typically continues. If you have type 2 diabetes, talk to your doctor about your actual diagnosis and how your prescription is coded; your coverage likely continues under the diabetes indication. One important line here: never misrepresent a diagnosis to get coverage. It's fraud, it can backfire on you and your doctor, and it's unnecessary — the options below are legitimate paths.

Your 8 Options If Coverage Is Dropped

Confirm exactly what changed. Read the 2027 formulary. Sometimes it's a shift to prior authorization or step therapy — hoops, not a wall — rather than a full exclusion.
Check the diabetes indication. If you have type 2 diabetes, coverage likely continues. Talk to your doctor about your actual diagnosis — never misrepresent one.
Ask about the appeal or exception process. A documented medical-necessity exception with your doctor's support sometimes succeeds, especially with comorbidities like sleep apnea or hypertension.
Compare individual marketplace plans during Open Enrollment. It starts November 1. Formularies vary by plan, and some cover weight-loss GLP-1s — check the drug list before enrolling. A licensed advisor can check formularies across carriers for free.
Use manufacturer self-pay programs. LillyDirect (Zepbound) and NovoCare (Wegovy) offer direct prices commonly in the roughly $350–$500/month range — often half the list price.
Pay with HSA or FSA dollars. Prescription drugs are eligible expenses, so pre-tax money can meaningfully cut your real cost.
Be cautious with compounded versions. The FDA has warned about safety and quality issues with compounded semaglutide and tirzepatide.
Ask about the new oral GLP-1s. As the pills launch, ask your doctor whether one fits your treatment plan and what its pricing looks like.

The Marketplace Route: What to Check Before You Switch

If your employer plan drops the benefit entirely, an individual marketplace plan is worth a serious look — but only if you verify the drug coverage first. Every plan publishes a formulary, and they differ carrier to carrier and plan to plan. Before you enroll:

Search the plan's drug list for your specific medication — brand name, not just the class
Note the tier — a covered drug on a high tier can still mean a hefty copay or coinsurance
Check for prior authorization or step therapy requirements on the drug
Weigh the full picture — premium, deductible, and drug cost together, not just the drug line

Mark your calendar: November 1

Open Enrollment for individual marketplace plans starts November 1 — right around when 2027 employer benefit changes take effect. If your employer is dropping the benefit, that window is your chance to move to a plan whose formulary covers your medication. Miss it, and you'll generally need a qualifying life event to enroll mid-year.

If You End Up Paying Out of Pocket

Self-pay doesn't have to mean list price. Manufacturer direct programs — LillyDirect for Zepbound, NovoCare for Wegovy — commonly land in the roughly $350–$500/month range, often about half the list price. Running those payments through an HSA or FSA makes them pre-tax, which helps more than it sounds. And steer clear of shortcuts: the FDA has warned about safety and quality issues with compounded semaglutide and tirzepatide, so talk to your doctor before considering any alternative source. If cost is still out of reach, ask about the new oral GLP-1 options as they launch — their pricing may open another door.

Frequently Asked Questions

Why are employers dropping GLP-1 coverage for weight loss?

Cost, mostly. Total GLP-1 spending keeps climbing even as per-unit prices come down, because new oral GLP-1 pills are bringing in many first-time users. According to Business Group on Health, roughly 10% of employers that currently cover GLP-1s for weight loss plan to drop them in 2027, and a Mercer survey found about 6% of employers with 500+ workers dropped coverage in 2026 with about 5% more considering it for 2027. Even Cigna — an insurer — stopped covering the drugs for weight loss for its own employees as of July 2026.

Does losing weight-loss coverage affect my diabetes medication?

Usually not. These cuts almost always target the weight-loss indication — drugs like Wegovy, Zepbound, and Saxenda. Coverage for GLP-1s prescribed for type 2 diabetes, like Ozempic and Mounjaro, typically continues. If you have type 2 diabetes, your coverage likely isn't going anywhere.

How do I find out exactly what changed in my plan?

Read your 2027 formulary (drug list) and any plan-change notices from your employer. Sometimes the change isn't a full exclusion — it may be a shift to prior authorization, step therapy, or a higher tier. Those are very different situations, and knowing which one you're in determines your next move.

Can I appeal if my employer's plan stops covering my GLP-1?

Often, yes — ask about the plan's exception or appeal process. A documented medical-necessity exception with your doctor's support sometimes succeeds, especially if you have comorbidities like sleep apnea, hypertension, or heart disease. It's not guaranteed, but it costs nothing to ask, and your doctor's office has likely filed these before.

Do marketplace (ACA) plans cover GLP-1s for weight loss?

Some do — formularies vary by plan and carrier. If your employer plan drops the benefit, you can compare individual marketplace plans during Open Enrollment, which starts November 1. Check each plan's drug list before enrolling, because coverage, tiers, and prior-authorization rules differ. A licensed advisor can check formularies across carriers for free.

How much do GLP-1s cost if I pay out of pocket?

Manufacturer self-pay programs — like LillyDirect for Zepbound and NovoCare for Wegovy — offer direct prices commonly in the roughly $350–$500 per month range, often about half the list price. You can also use HSA or FSA dollars to pay pre-tax, which softens the hit further.

Is compounded semaglutide or tirzepatide a safe cheaper option?

Be cautious. The FDA has warned about safety and quality issues with compounded versions of these drugs. If you're considering any alternative sourcing, talk to your doctor first — the savings aren't worth an unverified product.

Should I ask my doctor about the new oral GLP-1 pills?

Yes — it's worth a conversation. New oral GLP-1 options are launching, and their pricing may differ from the injectables. Your doctor can tell you whether a pill makes clinical sense for you and what it's likely to cost under your coverage — or without it.

Find a Plan That Covers Your GLP-1

Formularies vary widely between marketplace plans — some cover weight-loss GLP-1s and some don't. Our licensed advisors can check drug lists across carriers in your area, flag prior-authorization requirements, and help you weigh premiums against real drug costs. It's free.